Outcomes with transcatheter aortic valve replacement for aortic stenosis in rheumatoid arthritis: an observational study
Main finding · All-cause mortalityResult — go to the resultOdds ratio 1.29 95% CI 0.73–2.29Authors' conclusion
In this large observational study, TAVR was not associated with excess short- or long-term risk in patients with RA.
Study context
- Population
- Participants with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), TriNetX Research Network1,374 per cohort after matching
- Participants
- 1,374 vs 1,374
- Exposure
- TAVR in RA vs without RA
- RA+n = 1,374
- RA-n = 1,374reference
- Outcome
- 30-day all-cause mortality
- Follow-up
- 30 days
Methodological detailsmulticentre registry (TriNetX Research Network), matched, Cox regression, Before matching: 1414 RA+ (4.3%) and 39 004 RA- eligible
- Multicentre registry (TriNetX Research Network)
- Matched
- Cox regression
- Before matching: 1414 RA+ (4.3%) and 39 004 RA- eligible
Main finding
All-cause mortality
Odds ratio
1.29
95% CI 0.73–2.29
By group
RA+vs RA-
OR 1.29 (95% CI 0.73–2.29)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Other 30-day endpoints (permanent pacemaker implantation, ischaemic stroke, acute kidney injury, MI, cardiogenic shock, major vascular complications, major or life-threatening bleeding)
- No significant differences in other endpoints
- Matched cohort
Stroke, MI and hospitalization · 5 years
- Similar between RA+ and RA-; Hazard ratios (HRs) concordant with OR estimates
- Matched cohort
Outcomes by sex (RA patients, sex-based analyses)
- Outcomes did not differ by sex
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Outcomes with transcatheter aortic valve replacement for aortic stenosis in rheumatoid arthritis: an observational study. Rheumatology (Oxford). Published 28 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →